Hiring antibodies as nanotechnology builders

December 03, 2019

What if we could use antibodies as functional tools for nanotechnology applications? A group of researchers at the University of Rome Tor Vergata started from this simple question and the results of their research are now published in Nature Communications.

Nanotechnology enables the design and fabrication of molecular structures of nanoscale dimensions that hold a great potential for several applications in the near future, including biomedicine. A convenient way to make such nanostructures is to employ synthetic DNA as the building material. These days it is possible to design and synthetize DNA strands that, by simple and predictable interactions, bind to each other just like Lego bricks, and form beautiful 2D and 3D geometries in a very controllable and precise fashion. To date, many nanoscale shapes have been created using DNA bricks, ranging from nanoboxes to more complex geometries, such as a nanoscale Monalisa. To allow potential applications of these nanostructures, however, it would be extremely important to design them so that their assembly and disassembly could be guided by molecular cues of clinical relevance.

Now a research group at the University of Rome, Tor Vergata has shown that it is possible to recruit antibodies as molecular builders to build or dismantle DNA nanostructures.

The function of antibodies in our body is to recognize and bind to a specific target (i.e. the antigen), which is often a foreign molecule or protein. For this reason, antibodies are ideal biomarkers because they are produced by our body to target foreign molecules in our blood. Each antibody has its own target and therefore does its job in a highly specific and precise way.

"This project started a couple of years ago when we realized that this amazing functionality of antibodies (recognize and bind to a specific molecule) could be repurposed for nanotech applications", says Francesco Ricci, professor at the University of Rome Tor Vergata and senior author of the manuscript. "We had the idea of utilizing antibodies as molecular workers to build nanoscale structures".

"To do this, we employed DNA bricks that bind to each other and form nanostructures of tubular shape", says Simona Ranallo, a post-doc researcher in the group of Prof. Ricci and first author of the manuscript, "we then re-engineered such bricks with recognition tags (antigens) so that their assembly is initiated by a specific antibody. The nanotube structure can thus only built up when the antibody is present in the sample!"

"Antibodies are highly specialized workers" adds Ricci, "there are thousands of distinct antibodies in our body each recognizing its own antigen. We took advantage of this amazing feature and designed different bricks that can assemble with different specific antibodies".

"We took a step further" continues Ricci, "we engineered our DNA bricks so that not only they assemble into the desired nanostructure in the presence of a specific antibody, but they can also be completely dismantled by a second antibody worker".

This strategy demonstrates the possibility to design intelligent nanostructures that can be built and destroyed in the presence of a specific biomarker. This could have potential applications in the biomedical field, either in diagnostics or therapeutics.

Università Roma Tor Vergata

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.